Embodying the hope of curing cancer

Gustave Roussy is the leading Comprehensive Cancer Centre in Europe and continues to work to maintain its position among the ten world leaders in Oncology research and clinical care. As an integrated centre for research, treatment and teaching, the Institute manages patients of any age with every type of cancer and has particular expertise in the treatment of rare and complex tumours.

In order to offer a care environment which is exposed to day-to-day life, the Institute is committed to explore all possibilities of innovation whether they are in the field of therapy or in the development of services.

By extending scientific frontiers and constantly progressing in patient care, Gustave Roussy carries the hope of curing cancer in the 21st century.
By bringing together talented individuals, Gustave Roussy has become a driver of progress and a leader in advanced medicine. 300 researchers are engaged in every aspect of research in oncology: fundamental, clinical and translational. Very close collaboration between research workers and doctors at the Institute means that we can offer our patients access to the latest therapeutic advances within the shortest time-scale.

The effectiveness of the Gustave Roussy model of an integrated centre for research and clinical practice is reflected in the impact of its scientific publications and the prominence of its researchers at international conferences. The Institute’s teams are devoted principally to 3 research priorities:

- **Precision medicine** aims to offer targeted therapy, in particular by virtue of high throughput genomic analysis.
- Gustave Roussy is a pathfinder in **immunotherapy**, which harnesses the patient’s own immune system to treat the disease. Research conducted under the aegis of GRIP (Gustave Roussy’s Immunotherapy Programme) is opening up novel therapeutic prospects.
- **DNA repair** studies are improving our understanding of molecular mechanisms.

### Cutting-edge research

- 67 immunotherapy trials opened in 2016
- 81 patent families in the portfolio
- 417 medical research trials, 366 of which are therapeutic trials
- 300 research workers
Gustave Roussy declares its commitment to being a motor of progress in oncology in terms both of therapy and of care pathways. With innovative treatment which is the least invasive possible and is delivered under the safest conditions, the Institute offers its cancer patients high quality care from diagnosis to treatment. Gustave Roussy’s patients have access to a complete therapeutic “toolkit”: Medical Oncology, Chemotherapy, Radiotherapy, Surgery, Interventional Radiology, Reparative Surgery and Robotic Surgery. As a result of the successful marrying of research and clinical care, advances made in research are translated with little delay into clinical trials and then into treatment offered to the greatest number. The Drug Development Department (DITEP) facilitates patient access to novel therapies. Gustave Roussy intends to renew the relationship between patient and hospital by developing its services, so as to extend them from care to “taking care”. Through “Infiniment Vous”, an ambitious service development programme, Gustave Roussy’s doctors, nurses, patients and donors are collaborating to build a hospital which is more open and more attentive to human needs.

11,250 new patients

48,200 patients seen in outpatient consultations

247,200 medical consultations

24% of patients enrolled in interventional research
Gustave Roussy is committed to teaching and transmission of its expertise in the training of doctors, researchers, nurses, students and others involved in the care of cancer patients. These high quality teaching programmes are delivered by recognised experts and contributors to advances in oncology, and facilitate the rapid spread of knowledge of new treatments and the ongoing development of skills.

The École des Sciences du Cancer was established by Gustave Roussy and the Paris Sud University in 2012 and is unique in France. Students and staff are trained by a top-grade teaching body for the new career posts in oncology through courses leading to degrees and other qualifications.

In responding to the challenges posed by innovative treatments, the School has developed a modern teaching model based on visual aids, information technology and participatory learning. A complete digital teaching resource now comprises more than 1,000 videos and 750 hours of on-line training material.

In addition, the École Doctorale de Cancérologie (Doctoral Oncology School) is the only doctoral programme in France restricted to oncology. Its annual intake of 55 new doctoral students have a choice between 85 Research Units.

50 seminars and master classes

214 specialist doctors involved in teaching and 23 university teachers

343 publications in journals with an impact factor above 10

1,012 videos on line
Supporting us

A “private establishment of collective benefit”, the Institute, just like the Gustave Roussy Research Foundation, is authorised to receive donations and bequests. The generosity of our donors and sponsors is an essential component of support for our research and care teams. It is a real driver of progress. It contributes to financing innovative research projects and care and quality of life for patients. Donations and bequests received by the Institute give Gustave Roussy staff the means to make further advances in the fight against all cancers; in fundamental, clinical and translational research; and in improving patients’ quality of life.

In 2016, donations to the Institute and to the Fondation Gustave Roussy financed major projects: acquisition of latest generation equipment, renovation of departments, establishment of research teams and innovative programmes dedicated to research and to patient care.

Financial transparency, good management of donations and respect for the wishes of donors are constants at Gustave Roussy, which, since 2009, has held the Charter Committee’s “Donate in confidence” accreditation. This approval certifies the transparency of fundraising procedures and good management of donations received.

+67%
company sponsorship compared with 2015

12.94 M€
of donations to the Institute, i.e. +11% by comparison with 2015

20.7 M€
donations and bequests raised by the Institute and the Fondation Gustave Roussy in 2016
Gustave Roussy
in figures

**WORK ACTIVITY**

3,100 salaried staff,
of whom 1,200 are nurses

74 M€ devoted to research

367.1 M€ total budget

**RESEARCH**

417 medical research studies

342 publications with an impact factor above 10

24% of patients participating in interventional research

**TREATMENT**

444 beds and 105 Day Hospital places on the Villejuif and Chevilly-Larue campuses

48,200 patients seen in outpatient consultations

126,000 hospital episodes, of which 84% were in ambulatory care

**TEACHING**

26 University degrees

3,000 staff and students trained per year

59,000 hours devoted to teaching, 5,000 being at University level
Best efforts in the service of medical excellence.

Driven forwards by Gustave Roussy’s values of creativity, dynamism and collaboration, the Institute’s research teams, teachers, doctors and nurses put innovation at the heart of all of their activities.

"Gustave Roussy is a motivator of progress and a contributor to a human, scientific and technological revolution. It embodies hopes of curing cancer by pushing back the frontiers of knowledge."

Professor Alexander Eggermont,
Gustave Roussy General Director

114, rue Édouard-Vaillant
94805 Villejuif Cedex - France

www.gustaveroussy.fr/en